Abstract
Type 2 diabetes mellitus and heart failure are closely related, patients with type 2 diabetes mellitus have a higher risk of developing heart failure, and those with heart failure are at increased risk of developing type 2 diabetes. Although no specific randomized clinical trials have been conducted to test the effect of cardiovascular therapies (drugs and/or devices) in diabetic patients with heart failure, a lot of evidence shows that all interventions effective in improving prognosis in patients with heart failure reduced ejection fraction are equally beneficial in patients with and without diabetes. However, the use of disease-modifying drugs in patients with diabetes and heart failure reduced ejection fraction is a clinical challenge due to the increased risk of adverse effects. For example, β-blockers are underutilized in diabetic patients due to the theoretical unfavorable effects on glucose metabolism as well as the use of drugs that interact with the renin-angiotensin system can be challenged in patients with diabetic nephropathy because of the risk of hyperkalemia. This review outlines the current use of disease-modifying drugs in diabetic patients with heart failure reduced ejection fraction. In addition, the role of novel pharmacologic agents as type 2 sodium-glucose co-transporter inhibitors (SGLT2ii) is discussed.
Similar content being viewed by others
References
Metra M, Teerlink JR (2017) Heart failure. Lancet (London, England) 390:1981–1995. https://doi.org/10.1016/S0140-6736(17)31071-1
Murphy SP, Ibrahim NE, Januzzi JL Jr (2020) Heart failure with reduced ejection fraction: a review. JAMA 324:488–504. https://doi.org/10.1001/jama.2020.10262
DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, Hu FB, Kahn CR, Raz I, Shulman GI, Simonson DC, Testa MA, Weiss R (2015) Type 2 diabetes mellitus. Nat Rev Dis Primers 1:15019. https://doi.org/10.1038/nrdp.2015.19
Kaul U, Ray S, Prabhakar D, Kochar A, Sharma K, Hazra PK, Chandra S, Solanki D, Dutta AL, Kumar V, Rao MS, Oomman A, Dani S, Pinto B, Raghu TR (2020) Consensus document: management of heart failure in type 2 diabetes mellitus. Heart Fail Rev. https://doi.org/10.1007/s10741-020-09955-7
Dillmann WH (2019) Diabetic Cardiomyopathy. Circ Res 124:1160–1162. https://doi.org/10.1161/CIRCRESAHA.118.314665
Wilkinson MJ, Zadourian A, Taub PR (2019) Heart failure and diabetes mellitus: defining the problem and exploring the interrelationship. Am J Cardiol 124:S3–S11. https://doi.org/10.1016/j.amjcard.2019.10.024
Lehrke M, Marx N (2017) Diabetes mellitus and heart failure. Am J Med 130:S40–S50. https://doi.org/10.1016/j.amjmed.2017.04.010
Shaw JA, Cooper ME (2020) Contemporary management of heart failure in patients with diabetes. Diabetes Care 43:2895–2903. https://doi.org/10.2337/dc20-2173
Naegele M, Flammer AJ, Enseleit F, Ruschitzka F (2016) Medical therapy of heart failure with reduced ejection fraction: current evidence and new developments. Swiss Med Wkly 146:14295. https://doi.org/10.4414/smw.2016.14295
Ge Z, Li A, McNamara J, Dos Remedios C, Lal S (2019) Pathogenesis and pathophysiology of heart failure with reduced ejection fraction: translation to human studies. Heart Fail Rev 24:743–758. https://doi.org/10.1007/s10741-019-09806-0
Shearer F, Lang CC, Struthers AD (2013) Renin-angiotensin-aldosterone system inhibitors in heart failure. Clin Pharmacol Ther 94:459–467. https://doi.org/10.1038/clpt.2013.135
Kishi T (2012) Heart failure as an autonomic nervous system dysfunction. J Cardiol 59:117–122. https://doi.org/10.1016/j.jjcc.2011.12.006
Tanai E, Frantz S (2015) Pathophysiology of heart failure. Compr Physiol 6:187–214. https://doi.org/10.1002/cphy.c140055
Savinova OV, Gerdes AM (2012) Myocyte changes in heart failure. Heart Fail Clin 8:1–6. https://doi.org/10.1016/j.hfc.2011.08.004
Frangogiannis NG (2019) The extracellular matrix in ischemic and nonischemic heart failure. Circ Res 125:117–146. https://doi.org/10.1161/CIRCRESAHA.119.311148
Dirkx E, da Costa Martins PA, De Windt LJ (2013) Regulation of fetal gene expression in heart failure. Biochem Biophys Acta 1832:2414–2424. https://doi.org/10.1016/j.bbadis.2013.07.023
Poole-Wilson PA (2003) ACE inhibitors and ARBs in chronic heart failure: the established, the expected, and the pragmatic. Med Clin North Am 87:373–389. https://doi.org/10.1016/s0025-7125(02)00174-8
Erhardt LR (2005) A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure. Int J Clin Pract 59:571–578. https://doi.org/10.1111/j.1368-5031.2005.00513.x
Klapholz M (2009) Beta-blocker use for the stages of heart failure. Mayo Clin Proc 84:718–729. https://doi.org/10.4065/84.8.718
Pitt B, Pedro Ferreira J, Zannad F (2017) Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives. Eur Heart J Cardiovasc Pharmacother 31:48–57. https://doi.org/10.1093/ehjcvp/pvw016
Khder Y, Shi V, McMurray J, Lefkowitz MP (2017) Sacubitril/valsartan (LCZ696) in heart failure. Handb Exp Pharmacol 243:133–165. https://doi.org/10.1007/164_2016_77
Custodio JS Jr, Duraes AR, Abreu M, Albuquerque Rocha N, Roever L (2018) SGLT2 inhibition and heart failure-current concepts. Heart Fail Rev 23:409–418. https://doi.org/10.1007/s10741-018-9703-2
Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M (2020) SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet (London, England) 396:819–829. https://doi.org/10.1016/S0140-6736(20)31824-9
Garcia-Ropero A, Santos-Gallego CG, Zafar MU, Badimon JJ (2019) Metabolism of the failing heart and the impact of SGLT2 inhibitors. Expert Opin Drug Metab Toxicol 15:275–285. https://doi.org/10.1080/17425255.2019.1588886
Lopaschuk GD, Verma S (2020) Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. J Am Coll Cardiol Basic Trans Science 5:632–644. https://doi.org/10.1016/j.jacbts.2020.02.004
Cruickshank JM (2002) Beta-blockers and diabetes: the bad guys come good. Cardiovasc Drugs Ther 16:457–470. https://doi.org/10.1023/a:1022146721098
Mills GA, Horn JR (1985) Beta-blockers and glucose control. Drug Intell Clin Pharm 19:246–251. https://doi.org/10.1177/106002808501900401
Ozyıldız AG, Eroglu S, Bal U, Atar I, Okyay K, Muderrisoglu H (2017) Effects of carvedilol compared to nebivolol on insulin resistance and lipid profile in patients with essential hypertension. J Cardiovasc Pharmacol Ther 22:65–70. https://doi.org/10.1177/1074248416644987
Sanon VP, Sanon S, Kanakia R, Yu H, Araj F, Oliveros R, Chilton R (2014) Hypoglycemia from a cardiologist’s perspective. Clin Cardiol 37:499–504. https://doi.org/10.1002/clc.22288
Nandish S, Wyatt J, Oliveros R, Zion AS, Lujan M, Chilton R (2010) A cardiologist’s view of hypoglycemia. Curr Atheroscler Rep 12:88–95. https://doi.org/10.1007/s11883-010-0093-8
Giles TD (2002) Use of beta-blockers for heart failure in patients with diabetes mellitus. Postgrad Med 112:32–37. https://doi.org/10.3810/pgm.11.2002.suppl22.118
Effect of metoprolol CR/XL in chronic heart failure (1999) Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001–2007
Deedwania PC, Giles TD, Klibaner M, Ghali JK, Herlitz J, Hildebrandt P, Kjekshus J, Spinar J, Vitovec J, Stanbrook H, Wikstrand J, MERIT-HF Study Group (2005) Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 149:159–167. https://doi.org/10.1016/j.ahj.2004.05.056
Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, Rhodes S, Barrett M, Fonarow GC, Greenberg B, Heidenreich PA, Knabel T, Konstam MA, Steimle A, Warner Stevenson L (2003) Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 41:1529–1538. https://doi.org/10.1016/s0735-1097(03)00262-6
Haas SJ, Vos T, Gilbert RE, Krum H (2003) Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 146:848–853. https://doi.org/10.1016/S0002-8703(03)00403-4
Wai B, Kearney LG, Hare DL, Ord M, Burrell LM, Srivastava PM (2012) Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control. Cardiovasc Diabetol 11:14. https://doi.org/10.1186/1475-2840-11-14
Masarone D, Martucci ML, Errigo V, Pacileo G (2021) The use of β-blockers in heart failure with reduced ejection fraction. J Cardiovasc Dev Dis 8(9):101. https://doi.org/10.3390/jcdd8090101
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C (2017) ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 136:137–161. https://doi.org/10.1161/CIR.0000000000000509
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, Document Reviewers (2016) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18(8):891–975. https://doi.org/10.1002/ejhf.592
Investigators SOLVD, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293–302. https://doi.org/10.1056/NEJM199108013250501
Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown Jr. EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327(10):669–677. https://doi.org/10.1056/NEJM199209033271001
Swedberg K, Kjekshus J (1988) Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Am J Cardiol 62(2):60A-66A. https://doi.org/10.1016/s0002-9149(88)80087-0
Carson P, Johnson G, Fletcher R, Cohn J (1996) Vasodilators in heart failure. Conclusions from V-HeFT II and rationale for V-HeFT III. Drugs 47(Suppl 4):47–57; discussion 57–8. https://doi.org/10.2165/00003495-199400474-00008
Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342(3):145–153. https://doi.org/10.1056/NEJM200001203420301
Gerstein HC (2002) Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes Metab Res Rev 18:82–85. https://doi.org/10.1002/dmrr.285
Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC (1995) A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 333:670–1676. https://doi.org/10.1056/NEJM199512213332503
Peters DC, Noble S, Plosker GL (1998) Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders. Drugs 56:871–893. https://doi.org/10.2165/00003495-199856050-00014
Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, Granger CB, Hradec J, Kuch J, McKelvie RS, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Held P, Solomon SD, Yusuf S, Swedberg K, Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees (2004) Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 110:2618–2626. https://doi.org/10.1161/01.CIR.0000146819.43235.A9
MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, Pfeffer MA, McMurray JJ, Investigators CHARM (2008) Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 29:1377–1385. https://doi.org/10.1093/eurheartj/ehn153
Cohn JN, Tognoni G (2001) Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345(23):1667–75. https://doi.org/10.1056/NEJMoa010713
Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA (2009) HEAAL Investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomized, double-blind trial. Lancet 374:1840–1848. https://doi.org/10.1016/S0140-6736(09)61913-9.
Kiernan MS, Wentworth D, Francis G, Martinez FA, Dickstein K, Komajda M, Zannad F, Neaton JD, Konstam MA (2012) Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial. Eur J Heart Fail 14:1401–1409. https://doi.org/10.1093/eurjhf/hfs145
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709–717.https://doi.org/10.1056/NEJM199909023411001
Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, EMPHASIS-HF Study Group (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11–21. https://doi.org/10.1056/NEJMoa1009492
Dojki FK, Bakris G (2017) Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease. Curr Opin Nephrol Hypertens 26:368–374. https://doi.org/10.1097/MNH.0000000000000340
Rico-Mesa JS, White A, Ahmadian-Tehrani A, Anderson AS (2020) Mineralocorticoid receptor antagonists: a comprehensive review of finerenone. Curr Cardiol Rep 22:140. https://doi.org/10.1007/s11886-020-01399-7
Filippatos G, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H, Maggioni AP, Ponikowski P, Voors AA, Zannad F, Kim SY, Nowack C, Palombo G, Kolkhof P, Kimmeskamp-Kirschbaum N, Pieper A, Pitt B (2016) A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J 37:2105–2114. https://doi.org/10.1093/eurheartj/ehw132
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G (2020) FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383(23):2219–2229. https://doi.org/10.1056/NEJMoa2025845
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, Investigators PARADIGM-HF, Committees, (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004. https://doi.org/10.1056/NEJMoa1409077
Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, Rouleau JL, Swedberg K, Lefkowitz M, Shi VC, Desai AS, McMurray J, Solomon SD (2017) Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol 5:333–340. https://doi.org/10.1016/S2213-8587(17)30087-6
Seferovic JP, Solomon SD, Seely EW (2020) Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control. Ther Adv Endocrinol Metab 11:2042018820970444. https://doi.org/10.1177/2042018820970444
Khan MS, Felker GM, Piña IL, Camacho A, Bapat D, Ibrahim NE, Maisel AS, Prescott MF, Ward JH, Solomon SD, Januzzi JL, Butler J (2021) Reverse cardiac remodeling following initiation of sacubitril/valsartan in patients with heart failure with and without diabetes. JACC Heart failure 9:137–145. https://doi.org/10.1016/j.jchf.2020.09.014
Packer M, Claggett B, Lefkowitz MP, McMurray JJV, Rouleau JL, Solomon SD, Zile MR (2018) Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol 6(7):547–554. https://doi.org/10.1016/S2213-8587(18)30100-1
Ferrari F, Martins VM, Scheffel RS, da Silveira AD, Motta MT, Moriguchi EH, Santos RD, Stein R (2021) The role of sodium-glucose cotransporter-2 inhibitors in patients with heart failure, regardless of diabetes status: focus on cardiovascular disease. Ann Pharmacother 1060028020985111. Advance online publication. https://doi.org/10.1177/1060028020985111
Starr JA, Pinner NA, Lisenby KM, Osmonson A (2021) Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction. Pharmacotherapy. https://doi.org/10.1002/phar.2527
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, Investigators EMPA-REGOUTCOME (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128. https://doi.org/10.1056/NEJMoa1504720
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, CANVAS Program Collaborative Group (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657. https://doi.org/10.1056/NEJMoa1611925
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS (2019) DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347–357. https://doi.org/10.1056/NEJMoa1812389
Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney DZI, McGuire DK (2020) VERTIS CV Investigators. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 383(15):1425–1435. https://doi.org/10.1056/NEJMoa2004967
McMurray J, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JGDAPA-HF, Committees T, Investigators, (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995–2008. https://doi.org/10.1056/NEJMoa1911303
Curtain JP, Docherty KF, Jhund PS, Petrie MC, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Langkilde AM, Sjöstrand M, Solomon SD, McMurray JJV (2021) Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J 42(36):3727–3738. https://doi.org/10.1093/eurheartj/ehab560
Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett J, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Vinh PN, Schou M, Tereshchenko S, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Johanson P, Greasley PJ, Boulton D, Bengtsson O, Jhund PS, McMurray JJV (2020) Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA 323(14):1353–1368. https://doi.org/10.1001/jama.2020.1906
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuquiure E, EMPEROR-Reduced Trial Investigators, (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383:1413–1424. https://doi.org/10.1056/NEJMoa2022190
Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT, Berry C, Chong V, Coyle L, Docherty KF, Dreisbach JG, Labinjoh C, Lang NN, Lennie V, McConnachie A, Murphy CL, Petrie CJ, Petrie JR, Speirits IA, Sourbron S, Welsh P, Woodward R, Radjenovic A, Mark PB, McMurray JJV, Jhund PS, Petrie MC, Sattar N (2021) Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation 143(6):516–525. https://doi.org/10.1161/CIRCULATIONAHA.120.052186
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A, ESC Scientific Document Group (2021) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599–3726. https://doi.org/10.1093/eurheartj/ehab368.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Masarone, D., Pacileo, R. & Pacileo, G. Use of disease-modifying drugs in diabetic patients with heart failure with reduced ejection fraction. Heart Fail Rev 28, 657–665 (2023). https://doi.org/10.1007/s10741-021-10189-4
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10741-021-10189-4